Received Feb 19, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
interval between first dose and second dose was too short; vesicles; This non-serious case was reported by a other health professional and described the occurrence of vesicles in a 75-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. On 17-DEC-2024, the patient received the 1st dose of Shingrix. On 28-JAN-2025, the patient received the 2nd dose of Shingrix. On 24-DEC-2024, 7 days after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced vesicles (Verbatim: vesicles). On 28-JAN-2025, the patient experienced drug dose administration interval too short (Verbatim: interval between first dose and second dose was too short). On 28-JAN-2025, the outcome of the vesicles was resolved (duration 1 month 4 days). The outcome of the drug dose administration interval too short was unknown. It was unknown if the reporter considered the vesicles to be related to Shingrix and Shingrix. It was unknown if the company considered the vesicles to be related to Shingrix and Shingrix. Additional Information: GSK receipt date: 03-FEB-2025 The reporter reported that the patient had received Shingrix vaccine and experienced autoimmune disease diagnosed (Vesicles). The reporter mentioned that the expiry date of Shingrix was unknown. The patient received 2nd dose of Shingrix vaccine earlier than the recommended interval, which led to shortening of the vaccination scheduled.